Skip to main content

Greenberg Traurig Sponsors and Hosts NEIBC Breakfast Program 'Trends in the Israeli Life Sciences Arena'

BOSTON — April 23, 2015 — On Friday, April 24, from 8:00 – 10 a.m., Greenberg Traurig, LLP’s Boston office will sponsor and host the breakfast program, "Trends in the Israeli Life Sciences Arena," featuring guest speaker Elka Nir and a case study of Israeli medical device company Laryngoport Ltd. The New England-Israel Business Council (NEIBC), an organization focused on increasing economic development in Israel and New England by fostering cooperation, investment opportunities, and business relationships, organized the event. Greenberg Traurig shareholders and patent attorneys David J. Dykeman and Roman Fayerberg will serve as hosts and discussion moderators.

Dykeman is a registered patent attorney, co-chair of Greenberg Traurig’s Global Life Sciences & Medical Technology Group, and co-chair of the firm’s Intellectual Property (IP) Group in Boston. With over 18 years of experience in patents, intellectual property, and licensing, Dykeman focuses his practice on securing strategic worldwide intellectual property protection and related business strategy for high-tech clients, with particular expertise in medical devices, life sciences, biotechnology, and health care IT. Dykeman is the founding co-chair of the American Bar Association’s (ABA) Medical Devices Committee, and serves on the Editorial Advisory Board of Medical Device + Diagnostic Industry (MD+DI) Magazine.

Fayerberg is a registered patent attorney and shareholder in the firm’s Intellectual Property (IP) Group in Boston. He focuses his practice on the development and management of strategic patent portfolios and counseling clients on patent issues, primarily in technologies related to life sciences. He also advises clients in connection with intellectual property due diligence investigations for venture capital investment, mergers and acquisitions, and licensing opportunities. His patent practice builds on seven years of experience gained as a research and development engineer at C.R. Bard and Boston Scientific Corporation.